SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001193125-24-098492
Filing Date
2024-04-17
Accepted
2024-04-17 06:05:32
Documents
13
Period of Report
2024-04-12
Items
Item 1.01: Entry into a Material Definitive Agreement
Item 2.03: Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K d827422d8k.htm   iXBRL 8-K 26126
  Complete submission text file 0001193125-24-098492.txt   144791

Data Files

Seq Description Document Type Size
2 XBRL TAXONOMY EXTENSION SCHEMA cort-20240412.xsd EX-101.SCH 2850
3 XBRL TAXONOMY EXTENSION LABEL LINKBASE cort-20240412_lab.xml EX-101.LAB 17235
4 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE cort-20240412_pre.xml EX-101.PRE 10812
17 EXTRACTED XBRL INSTANCE DOCUMENT d827422d8k_htm.xml XML 3533
Mailing Address 149 COMMONWEALTH DRIVE MENLO PARK CA 94025
Business Address 149 COMMONWEALTH DRIVE MENLO PARK CA 94025 650.688.8803
CORCEPT THERAPEUTICS INC (Filer) CIK: 0001088856 (see all company filings)

IRS No.: 770487658 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 000-50679 | Film No.: 24849310
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)